Background: Subclinical hypothyroidism can be associated with the onset and progression of chronic heart failure.
Methods: We undertook a careful search of the literature aiming to review the possible pathogenetic mechanisms explaining the influence of subclinical hypothyroidism on the onset and progression of chronic heart failure.
Results: Thyroid hormones can influence the expression of genes involved in calcium handling and contractile properties of myocardiocytes. Subclinical hypothyroidism, therefore, can alter both cardiovascular morphology and function leading to changes in myocardiocytes shape and structure, and to alterations of both contractile and relaxing properties, impairing systolic as well as diastolic functions. Furthermore, it can favour dyslipidemia, endothelial dysfunction and diastolic hypertension, favouring atherogenesis and coronary heart disease, possibly evolving into chronic heart failure. Beside an influence on the onset of chronic heart failure, subclinical hypothyroidism can represent a risk factor for its progression, in particular hospitalization and mortality but the mechanisms involved need to be fully elucidated.
Conclusions: Subclinical hypothyroidism can be associated with the onset of chronic heart failure, because it can favour two frequent conditions that can evolve in heart failure: coronary heart disease and hypertension; it can also alter both cardiovascular morphology and function leading to heart failure progression in patients already affected through mechanisms still not completely understood.
Keywords: Amiodarone, cardiac remodeling, Chronic Heart Failure, levothyroxine replacement therapy, low T3 syndrome, Subclinical Hypothyroidism.
Comparison between Two Calcium Antagonists: Blood Pressure Reduction and Renal Effects in Hypertensive Patients with Type 2 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) The Heme Oxygenase System Selectively Modulates Proteins Implicated in Metabolism, Oxidative Stress and Inflammation in Spontaneously Hypertensive Rats
Current Pharmaceutical Design Lenticulostriate Artery and Lenticulostriate-artery Neural Complex: New Concept for Intracerebral Hemorrhage
Current Pharmaceutical Design Bone Mineral Density in Type 2 Diabetes Patients with Charcot Arthropathy
Current Diabetes Reviews Diverse combination therapies of Chinese Medicine in treating Hypertension
Current Vascular Pharmacology Clinical Science of Calcium Channel Blocker to Inhibit Hypertensive Vascular Injury
Current Hypertension Reviews Nephroangiosclerosis and Its Pharmacological Approach
Current Vascular Pharmacology Vaccination Against High Blood Pressure
Current Pharmaceutical Design Expression and Role of the Calcium-Sensing Receptor in the Blood Vessel Wall
Current Pharmaceutical Biotechnology Oleanolic Acid and Related Triterpenoids from Olives on Vascular Function: Molecular Mechanisms and Therapeutic Perspectives
Current Medicinal Chemistry Pannexin Channels: The Emerging Therapeutic Targets
Current Drug Targets Vascular Abnormalities in Essential Hypertension
Current Pharmaceutical Design Hypertensive Treatment and the Metabolic Syndrome
Current Hypertension Reviews NOS Inhibitors: Structure, Biological Activity and Mechanism of Action
Current Enzyme Inhibition A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Recent Advances on Stearoyl-Coa Desaturase Regulation in Fatty Liver Diseases
Current Drug Metabolism Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry The Resurgence of Aldosterone in Hypertension and Cardiovascular Disease
Current Hypertension Reviews Link between Metabolic Syndrome and Insulin Resistance
Current Vascular Pharmacology Chromogranin-A: A Multifaceted Cardiovascular Role in Health and Disease
Current Medicinal Chemistry